Immunocore Announces Multimillion Dollar Research Collaboration and Licensing Agreement

3rd July 2013

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs known as ImmTACs to treat cancer and viral disease, has announced that it has entered into a research collaboration and licensing agreement with Genentech, a member of the Roche Group, for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology.

Under the terms of the agreement, Immunocore will receive an initiation fee of between $10 and $20 million per programme and is eligible to receive in excess of $300 million in development and commercial milestone payments for each target programme and significant tiered royalties.

Founded in 2008, Immunocore Ltd is a privately owned, clinical-stage, biotechnology company developing a highly innovative platform technology that generates ImmTACs, novel drugs called for the treatment of cancer and viral infection. Immunocore traces its roots to Avidex Ltd, founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.

Press release sign up